Background: Statins have been reported to reduce the rates of recurrence and improve the resolution of chronic subdural hematomas (cSDHs) treated surgically or conservatively. No studies have investigated the effect of statins in patients treated with middle meningeal artery embolization.
Methods: We performed a retrospective search of our cSDH database to identify patients treated with middle meningeal artery embolization alone. Only patients with at least 1 noncontrast computed tomography scan obtained 3-12 weeks after embolization were included. Hematoma volumes were measured at baseline and last noncontrast computed tomography available. The volumes, volume reduction, speed of resolution, and recurrence were compared between patients already receiving statin therapy when admitted and those who were not.
Results: Forty-six patients with 50 cSDHs were included (statins, 17 patients with 18 cSDHs vs. nonstatins, 29 patients with 32 cSDHs). The statin group had a significantly higher rate of hyperlipidemia (statin, 64.7% vs. nonstatin, 31%, P = 0.03) but similar demographics, remaining comorbidities, medications, and hematoma thickness, axial and coronal lengths, and baseline volumes. The time between procedure and last noncontrast computed tomography scan was similar between groups. There were no differences between the groups regarding volume reduction, final volume, speed of resolution, complete resolution, and recurrence.
Conclusions: Patients treated with middle meningeal artery embolization alone who were on statin therapy had no differences in cSDH resolution or recurrence compared to those who were not on statin therapy. It is possible that the anti-inflammatory effects of statins may not be relevant when supply to the dura is interrupted by treatment with embolization.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.wneu.2022.10.027 | DOI Listing |
JMIR Res Protoc
January 2025
Institute of Medical Sociology and Rehabilitation Science, Charité - Universitätsmedizin Berlin corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Background: Acquired neurological diseases entail significant changes and influence the relationship between a patient and their significant other. In the context of long-term rehabilitation, those affected collaborate with health care professionals who are expected to have a positive impact on the lives of the affected individuals.
Objective: This study aims to examine the changes in the relationship between the patient and their loved ones due to acquired neurological disorders and the influence of health care professionals on this relationship.
JAMA Netw Open
January 2025
Department of Public Health and Preventive Medicine, State University New York (SUNY) Upstate Medical University, Syracuse, New York.
Importance: Environmental service workers (ESWs) have a critical role within the hospital infrastructure and are at the frontline of infection prevention. ESWs are highly trained in managing all forms of regulated waste, which includes biohazardous waste, and are responsible for the overall patient experience, janitorial work, and infection prevention. Without environmental services, patients have a 6 times greater risk of being infected by pathogens from patients who previously occupied their room.
View Article and Find Full Text PDFJAMA Netw Open
January 2025
Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil.
Importance: The open-label randomized phase 2 LACOG0415 trial evaluated 3 treatment strategies for patients with advanced castration-sensitive prostate cancer (CSPC): androgen deprivation therapy (ADT) plus abiraterone acetate and prednisone (AAP), apalutamide (APA) alone, or APA plus AAP.
Objective: To investigate the association of ADT plus AAP, APA alone, or APA plus AAP with health-related quality of life (HRQOL) in patients with advanced CSPC in the LACOG0415 trial.
Design, Setting, And Participants: The LACOG0415 randomized clinical trial comprised 128 patients with advanced CSPC who were randomized (1:1:1) to 1 of 3 treatment arms from October 16, 2017, to April 23, 2019.
Anesth Analg
February 2025
Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Background: Several health care networks have fully adopted second-generation supraglottic airway (SGA) i-gel. Real-world evidence of enhanced patient safety after such practice change is lacking. We hypothesized that the implementation of i-gel compared to the previous LMA®-Unique™ would be associated with a lower risk of airway-related safety events.
View Article and Find Full Text PDFNeurology
January 2025
APHP- Salpêtrière Hospital, DMU BioGem, CNRS, INSERM, Paris Brain Institute, Sorbonne University.
Background And Objectives: Brain energy deficiency occurs at the early stage of Huntington disease (HD). Triheptanoin, a drug that targets the Krebs cycle, can restore a normal brain energetic profile in patients with HD. In this study, we aimed at assessing its efficacy on clinical and neuroimaging structural measures in HD.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!